GLENMARK PHARMACEUTICALS
|
GLENMARK PHARMACEUTICALS Last 5 Year Cashflow Statement History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Profit Before Tax | ₹569 Cr | ₹868 Cr | ₹1,441 Cr | ₹1,382 Cr | ₹1,096 Cr |
Adjustment | ₹1,010 Cr | ₹1,472 Cr | ₹787 Cr | ₹645 Cr | ₹636 Cr |
Changes In working Capital | ₹-797 Cr | ₹-1,074 Cr | ₹-561 Cr | ₹-386 Cr | ₹127 Cr |
Cash Flow after changes in Working Capital | ₹782 Cr | ₹1,266 Cr | ₹1,667 Cr | ₹1,641 Cr | ₹1,859 Cr |
Cash Flow from Operating Activities | ₹-265 Cr | ₹625 Cr | ₹1,109 Cr | ₹1,131 Cr | ₹1,392 Cr |
Cash Flow from Investing Activities | ₹4,561 Cr | ₹-528 Cr | ₹-333 Cr | ₹-675 Cr | ₹-784 Cr |
Cash Flow from Financing Activities | ₹-3,906 Cr | ₹-77 Cr | ₹-520 Cr | ₹-442 Cr | ₹-445 Cr |
Net Cash Inflow / Outflow | ₹389 Cr | ₹19 Cr | ₹255 Cr | ₹14 Cr | ₹164 Cr |
Opening Cash & Cash Equivalents | ₹1,443 Cr | ₹1,411 Cr | ₹1,138 Cr | ₹1,110 Cr | ₹936 Cr |
Cash & Cash Equivalent on Amalgamation / Take over / Merger | - | ₹0.67 Cr | - | - | - |
Cash & Cash Equivalent of Subsidiaries under liquidations | ₹-192 Cr | - | - | - | - |
Translation adjustment on reserves / op cash balalces frgn subsidiaries | - | - | - | - | - |
Effect of Foreign Exchange Fluctuations | ₹18 Cr | ₹12 Cr | ₹18 Cr | ₹14 Cr | ₹9.76 Cr |
Closing Cash & Cash Equivalent | ₹1,658 Cr | ₹1,443 Cr | ₹1,411 Cr | ₹1,138 Cr | ₹1,110 Cr |
Compare Cashflow Statement of peers of GLENMARK PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLENMARK PHARMACEUTICALS | ₹44,864.2 Cr | 2.6% | 6.3% | 88% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹451,603.0 Cr | 3.7% | 8.5% | 49.4% | Stock Analytics | |
DIVIS LABORATORIES | ₹160,862.0 Cr | 3.6% | 1.8% | 52.1% | Stock Analytics | |
CIPLA | ₹122,810.0 Cr | 3% | 1.9% | 20.9% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹114,946.0 Cr | 2.7% | 15.5% | 23.2% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹96,377.1 Cr | -1.6% | 1% | 43.9% | Stock Analytics |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK PHARMACEUTICALS | 2.6% |
6.3% |
88% |
SENSEX | 0.3% |
-2.5% |
10% |
You may also like the below Video Courses